History

Research and development work on sound pressure waves started in 2001 following extensive worldwide market analysis: the technology was in its infancy and the primary application was for the treatment of pain. The decision to subsequently focus on arthritis was based on several key factors: the multi-billion dollar market size; the forecasted growth rate over the next two decades as a result of the aging population; the fractured arthritis marketplace; the absence of any known cure for this degenerative disease; the inability of existing products to provide consistent long term pain relief without side effects; and the growing recognition of the need for combination therapy in the management of arthritis pain.

Repeated treatment success with a broader group of arthritis patients encouraged the company to trade mark the name enSonix, and to start the registration and clearance proceedings with the United States Food and Drug Administration (FDA).

The Toronto West Research Centre and Clinic was opened in 2003 to further provide clinical evidence and to refine the treatment protocols, primarily for patients with osteoarthritis.

To objectively monitor the response to the treatments, patients were required to complete the WOMAC questionnaire, which assesses their levels of pain, stiffness and range of motion. The FDA recommends the use of the WOMAC for clinical trials on osteoarthritis. After ten sessions, our enSonix therapy yielded treatment outcomes better than comparable leading drugs therapies for arthritis, and most importantly, it did so without side effects. Additionally, many patients reported an improvement in their sleep, reductions in anxiety and depression, and acceleration in the healing of soft tissue injuries.

Concurrent with its research efforts, the Company’s medical staff expanded the treatment protocols to include many non-pharmacologic therapies, as recommended by the American College of Rheumatology.

Encouraged by the consistent positive treatment outcomes using the enSonix sound pressure waves, the company developed the AquaSonix and enSonix@home devices, to provide additional and targeted delivery methods to a broader audience.

In 2006, the Company opened the AquaSonix Research and Treatment Centre in the therapy pool at St. Joseph’s Healthcare Hospital in Hamilton, Ontario. Additional clinical research trials for AquaSonix Therapy will be conducted at this site.